{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T15:52:04Z","timestamp":1698335524578},"reference-count":43,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2005,2,3]],"date-time":"2005-02-03T00:00:00Z","timestamp":1107388800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2005,3]]},"abstract":"<jats:p><jats:bold>Abstract:\u2002<\/jats:bold> The accomplishments of the Nordic Myeloma Study Group (NMSG) during its first 15\u2003yr are briefly surveyed, together with a discussion of principles guiding the group's clinical trials and of problems that need to be addressed in coming years. The group has so far carried out 12 clinical trials, comprising more than 2500 patients, spanning from minor phase II to large randomised phase III trials. At the time of writing, two randomised trials are running (comparing two doses of i.v. pamidronate, and melphalan\u2010prednisone (MP) vs. MP\u2010thalidomide to elderly patients). The group has strived for a simple organisation with much responsibility delegated to regional coordinators (Denmark 3, Norway 5, Sweden 5). With regard to trial design, the group has considered it important that studies are based on sound scientific questions, are simple to handle for the participants, population based, investigator initiated, include quality of life and health resources assessment as end\u2010points, and can be used as basis for diverse scientific spin\u2010off projects. Like other clinical trial groups, NMSG faces a number of challenges in coming years. The financial situation for independent investigator\u2010initiated trials is far from satisfactory, especially with regard to the resource\u2010consuming implementation of more stringent good clinical practice rules and ethical committee demands. NMSG has also encountered increasing difficulties in recruiting patients to recent trials, partly because of problems related to participating physicians (lack of support, laborious paper work, insufficient credit for participation). Solutions to these problems have to be found if industry\u2010independent clinical trial groups are to survive.<\/jats:p>","DOI":"10.1111\/j.1600-0609.2004.00379.x","type":"journal-article","created":{"date-parts":[[2005,2,3]],"date-time":"2005-02-03T23:19:09Z","timestamp":1107472749000},"page":"185-193","source":"Crossref","is-referenced-by-count":2,"title":["Nordic Myeloma Study Group, the first 15\u2003years: scientific collaboration and improvement of patient care"],"prefix":"10.1111","volume":"74","author":[{"given":"Erik","family":"Hippe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Westin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Finn","family":"Wisl\u00f6ff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,2,3]]},"reference":[{"key":"e_1_2_21_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1987.tb00173.x"},{"key":"e_1_2_21_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1991.tb01856.x"},{"key":"e_1_2_21_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1990.tb02564.x"},{"key":"e_1_2_21_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1993.tb00148.x"},{"key":"e_1_2_21_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1991.tb07951.x"},{"key":"e_1_2_21_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1992.tb00568.x"},{"key":"e_1_2_21_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1993.tb01597.x"},{"key":"e_1_2_21_9_2","first-page":"1331","article-title":"Human leukocyte interferon and intermittent high dose melphalan\u2010prednisone administration in the treatment of myeloma: a randomised clinical trial from the Myeloma Group of Central Sweden","volume":"68","author":"Ahre A","year":"1984","journal-title":"Treat Rep"},{"key":"e_1_2_21_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199005173222005"},{"key":"e_1_2_21_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1995.tb08364.x"},{"key":"e_1_2_21_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198402163100703"},{"key":"e_1_2_21_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1992.tb06400.x"},{"key":"e_1_2_21_14_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-124-2-199601150-00004"},{"key":"e_1_2_21_15_2","first-page":"7","article-title":"Impact on survival of high\u2010dose therapy with autologous stem cell support in patients younger than 60\u2003years with newly diagnosed multiple myeloma: a population\u2010based study. Nordic Myeloma Study Group","volume":"95","author":"Lenhoff S","year":"2000","journal-title":"Blood"},{"key":"e_1_2_21_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1995.tb05254.x"},{"key":"e_1_2_21_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199602223340802"},{"key":"e_1_2_21_18_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1996.352889.x"},{"key":"e_1_2_21_19_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1996.d01-1802.x"},{"key":"e_1_2_21_20_2","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-199712010-00009"},{"key":"e_1_2_21_21_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0609.2001.066005328.x"},{"key":"e_1_2_21_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0197-2456(96)00022-0"},{"key":"e_1_2_21_23_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01651.x"},{"key":"e_1_2_21_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1994.tb00190.x"},{"key":"e_1_2_21_25_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0609.2000.90221.x"},{"key":"e_1_2_21_26_2","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1182\/blood.V93.12.4144","article-title":"Serum hyaluronan in patients with multiple myeloma: correlation with survival and Ig concentration","volume":"93","author":"Dahl IM","year":"1999","journal-title":"Blood"},{"key":"e_1_2_21_27_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V91.3.806"},{"key":"e_1_2_21_28_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.2.388"},{"key":"e_1_2_21_29_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.7.2269"},{"key":"e_1_2_21_30_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-05-1406"},{"key":"e_1_2_21_31_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.8672495.x"},{"key":"e_1_2_21_32_2","doi-asserted-by":"publisher","DOI":"10.1089\/scd.1.1995.4.21"},{"key":"e_1_2_21_33_2","doi-asserted-by":"publisher","DOI":"10.1089\/scd.1.1996.5.237"},{"key":"e_1_2_21_34_2","doi-asserted-by":"publisher","DOI":"10.1089\/106161299320532"},{"key":"e_1_2_21_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(19980315\/15)17:5\/7<623::AID-SIM809>3.0.CO;2-5"},{"key":"e_1_2_21_36_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1026419414249"},{"key":"e_1_2_21_37_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01206.x"},{"key":"e_1_2_21_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)90326-4"},{"issue":"4","key":"e_1_2_21_39_2","first-page":"69","article-title":"Addressing the challenge of intergroup studies in oncology: the EORTC experience. European Organization for Research and Treatment of Cancer","volume":"38","author":"Zurlo A","year":"2002","journal-title":"Eur J Cancer"},{"key":"e_1_2_21_40_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002800051088"},{"key":"e_1_2_21_41_2","first-page":"15","article-title":"Originality, benefits and difficulties of clinical research performed by cooperative groups: the experience of an Italian lung cancer study group","volume":"8","author":"Gridelli C","year":"1999","journal-title":"Crit Rev Oncol Hematol"},{"key":"e_1_2_21_42_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.thj.6200064"},{"key":"e_1_2_21_43_2","article-title":"Impact of age on survival after intensive therapy in newly diagnosed multiple myeloma. The Nordic Myeloma Study Group (NMSG). American Society of Hematology, 46th Annual Meeting, 2004","author":"Lenhoff S","journal-title":"Abstract 924"},{"key":"e_1_2_21_44_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.04879.x"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.2004.00379.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0609.2004.00379.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T23:22:01Z","timestamp":1695770521000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.2004.00379.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,2,3]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,3]]}},"alternative-id":["10.1111\/j.1600-0609.2004.00379.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.2004.00379.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,2,3]]}}}